Home > Research > Publications & Outputs > Cathepsin S Levels and Survival Among Patients ...

Links

Text available via DOI:

View graph of relations

Cathepsin S Levels and Survival Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Published
  • Kimon Stamatelopoulos
  • Matthias Mueller-Hennessen
  • Georgios Georgiopoulos
  • Pedro Lopez-Ayala
  • Marco Sachse
  • Nikolaos I Vlachogiannis
  • Kateryna Sopova
  • Dimitrios Delialis
  • Francesca Bonini
  • Raphael Patras
  • Giorgia Ciliberti
  • Mehrshad Vafaie
  • Moritz Biener
  • Jasper Boeddinghaus
  • Thomas Nestelberger
  • Luca Koechlin
  • Simon Tual-Chalot
  • Ioannis Kanakakis
  • Hugo Katus
  • Ioakim Spyridopoulos
  • Christian Mueller
  • Evangelos Giannitsis
  • Konstantinos Stellos
Close
<mark>Journal publication date</mark>6/09/2022
<mark>Journal</mark>Journal of the American College of Cardiology
Issue number10
Volume80
Number of pages13
Pages (from-to)998-1010
Publication StatusPublished
Early online date29/08/22
<mark>Original language</mark>English

Abstract

BACKGROUND: Patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACS) are at high residual risk for long-term cardiovascular (CV) mortality. Cathepsin S (CTSS) is a lysosomal cysteine protease with elastolytic and collagenolytic activity that has been involved in atherosclerotic plaque rupture.

OBJECTIVES: The purpose of this study was to determine the following: 1) the prognostic value of circulating CTSS measured at patient admission for long-term mortality in NSTE-ACS; and 2) its additive value over the GRACE (Global Registry of Acute Coronary Events) risk score.

METHODS: This was a single-center cohort study, consecutively recruiting patients with adjudicated NSTE-ACS (n = 1,112) from the emergency department of an academic hospital. CTSS was measured in serum using enzyme-linked immunosorbent assay. All-cause mortality at 8 years was the primary endpoint. CV death was the secondary endpoint.

RESULTS: In total, 367 (33.0%) deaths were recorded. CTSS was associated with increased risk of all-cause mortality (HR for highest vs lowest quarter of CTSS: 1.89; 95% CI: 1.34-2.66; P < 0.001) and CV death (HR: 2.58; 95% CI: 1.15-5.77; P = 0.021) after adjusting for traditional CV risk factors, high-sensitivity C-reactive protein, left ventricular ejection fraction, high-sensitivity troponin-T, revascularization and index diagnosis (unstable angina/ non-ST-segment elevation myocardial infarction). When CTSS was added to the GRACE score, it conferred significant discrimination and reclassification value for all-cause mortality (Delta Harrell's C: 0.03; 95% CI: 0.012-0.047; P = 0.001; and net reclassification improvement = 0.202; P = 0.003) and CV death (AUC: 0.056; 95% CI: 0.017-0.095; P = 0.005; and net reclassification improvement = 0.390; P = 0.001) even after additionally considering high-sensitivity troponin-T and left ventricular ejection fraction.

CONCLUSIONS: Circulating CTSS is a predictor of long-term mortality and improves risk stratification of patients with NSTE-ACS over the GRACE score.

Bibliographic note

Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.